Shroom Scan #121: One dose reversed TBI damage a year later

Hi Shroomers. Big week for the case that fungi belong in serious medicine. We've got a psilocybin meta-analysis that should turn heads, a single-dose TBI result that came out of nowhere, and mushroom compounds stacking up against leukemia across 109 studies. Plus a growing hack that cuts cordyceps production costs using waste you're already making. Let's scan.

Killing cancer cells 🔪 Leftover Inocutis levis (Inocutis levis) substrate contains compounds that killed esophageal cancer cells in lab tests—even at small doses. The extract triggered cancer cell death and blocked growth signals that cancer depends on, while leaving healthy cells alone. Farming waste is becoming a source of real anticancer compounds.

The right bugs 🐛 Polysaccharides from two Lentinus mushrooms, L. polychrous and L. squarrosulus, survived the digestive tract 70–81% intact and went on to feed beneficial gut bacteria while crowding out harmful ones. This flipped key gut ratios in a healthy direction — Firmicutes/Bacteroidota dropped from 1.47 to 0.60, Blautia/Bacteroides from 1.43 to 0.13 — both linked to lower obesity and disease risk. Fermentation also dropped pH from 7.2 to 5.75, a sign the bacteria were actively producing the short-chain fatty acids that support gut, brain, and heart health.

Upgraded oysters 🦪 Growing oyster mushrooms (Pleurotus djamor and P. sajor-caju) on wheat straw spiked with zinc and selenium nanoparticles — made from the mushrooms' own cell extracts — significantly boosted their antioxidant and antibacterial potency. Zinc-treated P. djamor showed the strongest antioxidant activity and fought off Staph aureus, while selenium-treated versions of both species were most effective against E. coli. The method is self-contained: the mushroom makes the compounds that make it more powerful, with clear applications for food safety and natural medicine.

Mushrooms vs. leukemia 🧫 Across 109 studies and 53 mushroom species, compounds from reishi (Ganoderma lucidum), cordyceps (Cordyceps militaris), turkey tail (Trametes versicolor), and sun mushroom (Agaricus blazei) consistently killed leukemia cells by triggering programmed cell death and blocking key cancer growth pathways. One clinical trial showed turkey tail's polysaccharide PSK extended remission in leukemia patients by 418 days, while Sun mushroom's compound agaritine eliminated leukemia cells at concentrations as low as 2.7 μg/mL while leaving healthy cells unharmed. Clinical use is still limited by inconsistent extract quality and few large trials, but the depth of evidence across dozens of species makes medicinal mushrooms one of the most promising natural sources for future blood cancer research.

Reishi in the cancer clinic 💻 Reishi mushroom (Ganoderma lucidum) ranked as the 4th most searched supplement on Memorial Sloan Kettering's About Herbs database in 2025, reflecting how widely cancer patients are self-prescribing it — yet 60.5% of women on adjuvant cancer treatment never discuss supplement use with their doctors. The evidence for reishi during radiation is limited to preclinical data, and its spore supplements have been associated with elevated CA72-4 tumor markers in GI cancer patients, which can lead clinicians to misread disease progression. Reishi's antioxidant properties also raise a specific concern during cancer treatment: high-dose antioxidant supplements can theoretically protect tumor cells from radiation-induced damage, and one randomized trial in head and neck cancer found antioxidant use reduced short-term side effects but increased local recurrence.

The numbers 📈 Across 10 clinical trials, psilocybin-assisted therapy produced a large overall effect on depression (Cohen's d = 1.15), with controlled randomized trials alone showing d = 0.96 — still large by clinical standards — and no increased risk of serious side effects on dosing days. In the strongest 12-month follow-up study, 75% of participants maintained a treatment response and 58% were in full remission a year after just two psilocybin sessions. Evidence quality is rated low to moderate due to small samples and difficulty blinding participants to whether they took a psychedelic, but the signal holds up even after conservative sensitivity analyses, putting psilocybin among the most promising alternatives for the 20–30% of depression patients who don't respond to standard antidepressants.

Same destination, different roads 🛣 Psilocybin, ketamine, LSD, and even nitrous oxide (laughing gas) all disrupt the same overactive brain network through completely different receptor pathways, suggesting that quieting this network is the shared mechanism behind their antidepressant effects. A single psilocybin dose triggers new dendritic spine growth in the frontal cortex that persists for at least one month, offering a cellular explanation for why therapeutic effects outlast the drug by weeks or months. A landmark trial that administered ketamine to patients already under surgical anesthesia found that a significant portion of its antidepressant signal disappeared when the subjective high was blocked, directly implicating the conscious psychedelic experience as a key therapeutic ingredient rather than just the drug's chemistry.

One dose, one year later ⚡ A single psilocybin injection given a full year after traumatic brain injury reversed motor deficits and memory impairment in rats, restored depleted serotonin receptors (p = 0.001), and reduced the brain's chronic inflammation response — in a condition that currently has zero approved treatments. The drug only triggered these changes in injured brains, not healthy ones, suggesting it targets damage specifically rather than altering normal brain chemistry. With ~70 million TBIs happening annually and survivors often stuck with permanent deficits long after recovery plateaus, a single dose that reverses both receptor damage and neuroinflammation a year later puts psilocybin on the map as the first real pharmacological candidate for chronic TBI.

Better mushroom burger 🍔 Out of four formulations tested, the blend of banana blossom, wood ear (Auricularia auricula-judae), and edamame flour scored highest on both nutrition and taste, with the winning ratio outperforming all heavier single-ingredient variants. Shifting ingredient ratios significantly moved protein, carbohydrate content, texture, and aroma but had zero impact on fiber, color, or taste, meaning the mushroom's structural properties drive mouthfeel more than flavor. For food developers in the plant-based space, this positions wood ear as a functional texture ingredient worth centering formulations around, not just padding them with.

Waste feed 🌾 Spent substrate from beech mushroom (Hypsizygus marmoreus) — the leftover growing medium after harvest — boosted cordyceps (Cordyceps militaris) fruiting body yield by 35.33% and performed statistically on par with silkworm pupae powder, the costly animal-derived supplement that currently drives industrial production costs. The active ingredient is malic acid, naturally concentrated in the spent substrate, which alone increased yields by 20.97% by triggering 2,071 upregulated genes during the critical primordium stage, a nearly 8x larger genetic response than at the vegetative stage. Swapping silkworm pupae for on-site mushroom waste cuts 11–31% of production costs per kg of fresh cordyceps, with the biggest advantage going to facilities already growing multiple species and generating that waste in-house.